{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:43:51Z","timestamp":1773290631728,"version":"3.50.1"},"reference-count":67,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>As the life expectancy of individuals with hemophilia continues to increase, the complexity of balancing bleeding risks and thrombotic management has become increasingly critical in people with hemophilia with or at a high risk of thrombosis. Advances in hemophilia therapies such as extended half-life coagulation factors, non-factor therapies, rebalancing agents, and gene therapy have expanded treatment options for a variety of people with hemophilia. The thrombotic risk of people with hemophilia in general are relatively low as compared to those without hemophilia. However, antithrombotic therapy for prevention and treatment for thrombosis should still be considered in some situations, even in hemophilia. This clinical focus highlights the use of antithrombotic therapy in the management of thrombosis in people with hemophilia. A multidisciplinary, personalized approach is essential for optimizing the safety and efficacy of antithrombotic therapy in people with hemophilia with or at a high risk of thrombosis. High performance computer based multidimensional data analysis may help in establishing the personalized antithrombotic therapy in the future.<\/jats:p>","DOI":"10.1055\/a-2548-4192","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T19:10:26Z","timestamp":1740769826000},"page":"1060-1068","source":"Crossref","is-referenced-by-count":5,"title":["Antithrombotic Therapy in People with Hemophilia\u2014A Narrative Review"],"prefix":"10.1055","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1126-1498","authenticated-orcid":false,"given":"Azusa","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan"},{"name":"Department of Hematology and Oncology, Kansai Medical University Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0450-0331","authenticated-orcid":false,"given":"Shinichi","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6821-1504","authenticated-orcid":false,"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Medicine (Cardiology), Tokai University School of Medicine, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"102640","DOI":"10.1016\/j.rpth.2024.102640","article-title":"Gene therapy in hemophilia: the dawn of a new era","volume":"9","author":"R Gualtierotti","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"102308","DOI":"10.1016\/j.rpth.2023.102308","article-title":"The evolution of hemophilia therapeutics: an illustrated review","volume":"8","author":"M G Espa\u00f1ol","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.15182","article-title":"Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018","volume":"19","author":"S Hassan","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jacc.2021.12.017","article-title":"Inflammation, aging, and cardiovascular disease: JACC review topic of the week","volume":"79","author":"L Liberale","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1093\/ajh\/7.7.7S","article-title":"Established risk factors and coronary artery disease: the Framingham Study","volume":"7","author":"P W Wilson","year":"1994","journal-title":"Am J Hypertens"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/bloodadvances.2021005260","article-title":"Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study","volume":"6","author":"P Van Der Valk","year":"2022","journal-title":"Blood Adv"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/hae.14876","article-title":"Haemophilia and cardiovascular disease in Japan: low incidence rates from ADVANCE Japan baseline data","volume":"29","author":"A Nagao","year":"2023","journal-title":"Haemophilia"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1538-7836.2011.04499.x","article-title":"Factor VIII deficiency does not protect against atherosclerosis","volume":"10","author":"S Biere-Rafi","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ahj.2008.06.029","article-title":"Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis","volume":"156","author":"S Goto","year":"2008","journal-title":"Am Heart J"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/hae.12445","article-title":"Atrial fibrillation in patients with haemophilia: a cross-sectional evaluation in Europe","volume":"20","author":"R E Schutgens","year":"2014","journal-title":"Haemophilia"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"e8121","DOI":"10.1002\/ccr3.8121","article-title":"Portal vein thrombosis in a patient with severe hemophilia B: a challenging balanced management","volume":"12","author":"O Benitez-Hidalgo","year":"2024","journal-title":"Clin Case Rep"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/hae.14095","article-title":"Risk of deep venous thrombosis after total knee arthroplasty in patients with haemophilia A","volume":"26","author":"K Ono","year":"2020","journal-title":"Haemophilia"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/hae.14674","article-title":"Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A\u2014a modified Delphi consensus by the ADVANCE Working Group","volume":"29","author":"R Klamroth","year":"2023","journal-title":"Haemophilia"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"e900","DOI":"10.1097\/HS9.0000000000000900","article-title":"Antithrombotic treatment in patients with hemophilia: an EHA-ISTH-EAHAD-ESO clinical practice guidance","volume":"7","author":"R EG Schutgens","year":"2023","journal-title":"HemaSphere"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/hae.14874","article-title":"Guidance for the antithrombotic management of persons with haemophilia and cardiovascular disease","volume":"29","author":"P M Mannucci","year":"2023","journal-title":"Haemophilia"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/hae.15039","article-title":"Treatment of thrombotic cardiovascular diseases in people with haemophilia: a Japanese consensus study","volume":"30","author":"A Nagao","year":"2024","journal-title":"Haemophilia"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0044-1796629","article-title":"The evolution of hemophilia pharmacological treatments and therapeutic targets at the turn of the third millennium","volume":"51","author":"A Coppola","year":"2025","journal-title":"Semin Thromb Hemost"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"A von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"J Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"09","key":"ref20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"K J Pasi","year":"2017","journal-title":"N Engl J Med"},{"issue":"09","key":"ref21","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"explorer7 Investigators. Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"T Matsushita","year":"2023","journal-title":"N Engl J Med"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results","volume":"200","author":"J Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"issue":"08","key":"ref23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"J Mahlangu","year":"2023","journal-title":"N Engl J Med"},{"issue":"08","key":"ref24","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"S W Pipe","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with fidanacogene elaparvovec in adults with hemophilia B","volume":"391","author":"A Cuker","year":"2024","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1016\/0735-1097(88)92635-6","article-title":"Group I\u2013C. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"12","year":"1988","journal-title":"J Am Coll Cardiol"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"S Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41572-019-0090-3","article-title":"ST-segment elevation myocardial infarction","volume":"5","author":"B Vogel","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"G N Levine","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"17","key":"ref30","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJM199904293401713","article-title":"Antithrombotic therapy after coronary-artery stenting","volume":"340","author":"F Ferrer","year":"1999","journal-title":"N Engl J Med"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/cpt.2797","article-title":"Comparative effectiveness of ticagrelor, prasugrel, and clopidogrel for secondary prophylaxis in acute coronary syndrome: a propensity score-matched cohort study","volume":"113","author":"A Kumar","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"09","key":"ref32","doi-asserted-by":"crossref","first-page":"e034414","DOI":"10.1161\/JAHA.124.034414","article-title":"Impact of society guidelines on trends in use of newer P2Y12 inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention","volume":"13","author":"M O Mohamed","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"ref34","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"S D Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"23","key":"ref35","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"L Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"ref36","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"M P Bonaca","year":"2015","journal-title":"N Engl J Med"},{"issue":"09","key":"ref37","doi-asserted-by":"crossref","first-page":"e013242","DOI":"10.1161\/CIRCINTERVENTIONS.123.013242","article-title":"Short-term DAPT and DAPT de-escalation strategies for patients with acute coronary syndromes: a systematic review and network meta-analysis","volume":"16","author":"T Kuno","year":"2023","journal-title":"Circ Cardiovasc Interv"},{"issue":"24","key":"ref38","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"H Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"18","key":"ref39","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"M Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11239-022-02664-y","article-title":"Acute coronary syndrome in patients with hemophilia: a delicate balancing act","volume":"54","author":"J J Mayfield","year":"2022","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"ref41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4070\/kcj.2010.40.10.527","article-title":"Successful percutaneous coronary intervention for acute coronary syndrome in a patient with severe hemophilia a","volume":"40","author":"D-K Kim","year":"2010","journal-title":"Korean Circ J"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3122\/jabfm.2012.03.100270","article-title":"Current oral antiplatelets: focus update on prasugrel","volume":"25","author":"J John","year":"2012","journal-title":"J Am Board Fam Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"B K Koo","year":"2021","journal-title":"Lancet"},{"issue":"08","key":"ref44","doi-asserted-by":"crossref","first-page":"e0237022","DOI":"10.1371\/journal.pone.0237022","article-title":"Major bleeding risk and mortality associated with antiplatelet drugs in real-world clinical practice. A prospective cohort study","volume":"15","author":"J Bouget","year":"2020","journal-title":"PLoS One"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1111\/hae.13871","article-title":"ST-segment elevation myocardial infarction (STEMI) and pulmonary embolism in a hemophilia A patient receiving emicizumab and recombinant activated factor VII","volume":"26","author":"K Gundabolu","year":"2020","journal-title":"Haemophilia"},{"issue":"11","key":"ref46","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"C B Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"ref47","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"M R Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"ref48","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"R P Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/heartjnl-2016-309832","article-title":"Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation","volume":"103","author":"A J Camm","year":"2017","journal-title":"Heart"},{"key":"ref50","first-page":"qcaf002","article-title":"Temporal trends of prescription rates, oral anticoagulants dose, clinical outcomes and factors associated with non-anticoagulation in patients with incident atrial fibrillation","author":"J-N Liao","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"14","key":"ref51","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/CIRCULATIONAHA.118.036046","article-title":"Evolving changes of the use of oral anticoagulants and outcomes in patients with newly diagnosed atrial fibrillation in Taiwan","volume":"138","author":"T-F Chao","year":"2018","journal-title":"Circulation"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40256-024-00638-4","article-title":"Trends in oral anticoagulant use and individual expenditures across the United States from 2014 to 2020","volume":"24","author":"O S Alkhezi","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"issue":"13","key":"ref53","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"J W Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"22","key":"ref54","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"C Patrono","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.123.064556","article-title":"Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants","volume":"148","author":"R Aggarwal","year":"2023","journal-title":"Circulation"},{"issue":"20","key":"ref56","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Z Hijazi","year":"2016","journal-title":"Eur Heart J"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Z Hijazi","year":"2016","journal-title":"Lancet"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.thromres.2024.03.031","article-title":"Exploring the effects of factor Xa inhibitors on thrombin generation in people with haemophilia","volume":"237","author":"C Dix","year":"2024","journal-title":"Thromb Res"},{"issue":"18","key":"ref59","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"K Okumura","year":"2020","journal-title":"N Engl J Med"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/ehjcvp\/pvz076","article-title":"New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF","volume":"6","author":"S Goto","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"e0210103","DOI":"10.1371\/journal.pone.0210103","article-title":"Artificial intelligence to predict needs for urgent revascularization from 12-leads electrocardiography in emergency patients","volume":"14","author":"S Goto","year":"2019","journal-title":"PLoS One"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/s41467-021-22877-8","article-title":"Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms","volume":"12","author":"S Goto","year":"2021","journal-title":"Nat Commun"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"102141","DOI":"10.1016\/j.eclinm.2023.102141","article-title":"Deep learning-based model detects atrial septal defects from electrocardiography: a cross-sectional multicenter hospital-based study","volume":"63","author":"K Miura","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"10","key":"ref64","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1161\/CIRCULATIONAHA.121.058696","article-title":"Multinational federated learning approach to train ECG and echocardiogram models for hypertrophic cardiomyopathy detection","volume":"146","author":"S Goto","year":"2022","journal-title":"Circulation"},{"issue":"08","key":"ref65","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.5551\/jat.63798","article-title":"Detection of the relationship between the multi-dimensional data sets of serially measured blood pressure and the future risk of death in healthy elderly Japanese population","volume":"30","author":"M Nakayama","year":"2023","journal-title":"J Atheroscler Thromb"},{"issue":"05","key":"ref66","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/biomedicines9050445","article-title":"Laboratory monitoring of direct oral anticoagulants (DOACs)","volume":"9","author":"C Dunois","year":"2021","journal-title":"Biomedicines"},{"issue":"09","key":"ref67","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory monitoring in emicizumab-treated persons with hemophilia A","volume":"119","author":"J M\u00fcller","year":"2019","journal-title":"Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2548-4192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:45:33Z","timestamp":1761867933000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2548-4192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":67,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,10,30]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2548-4192","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,28]]},"published":{"date-parts":[[2025,2,28]]}}}